
浏览全部资源
扫码关注微信
重庆国际旅行卫生保健中心/重庆海关口岸门诊部,重庆 401147
张 朓,Email:zhangt236@126.com,研究方向:健康管理、预防接种、旅行医学咨询、传染病、群体性不明原因疾病、妇产科等。
刘启军,Email:cqithc_liu@163.com。
收稿:2024-09-14,
修回:2024-12-15,
录用:2024-12-25,
纸质出版:2025-07-28
移动端阅览
张朓,郝玉通,文海燕,等.粪便SDC2/TFPI2基因甲基化检测在结直肠癌筛查中的临床性能研究[J].重庆医科大学学报,2025,50(7):983-987.
Zhang Tiao,Hao Yutong,Wen Haiyan,et al.Clinical performance of fecal syndecan 2/tissue factor pathway inhibitor 2 gene methylation assay in colorectal cancer screening[J].Journal of Chongqing Medical University,2025,50(7):983-987.
张朓,郝玉通,文海燕,等.粪便SDC2/TFPI2基因甲基化检测在结直肠癌筛查中的临床性能研究[J].重庆医科大学学报,2025,50(7):983-987. DOI: 10.13406/j.cnki.cyxb.003786.
Zhang Tiao,Hao Yutong,Wen Haiyan,et al.Clinical performance of fecal syndecan 2/tissue factor pathway inhibitor 2 gene methylation assay in colorectal cancer screening[J].Journal of Chongqing Medical University,2025,50(7):983-987. DOI: 10.13406/j.cnki.cyxb.003786.
目的
2
探究粪便中蛋白聚糖2(syndecan 2,SDC2)和组织因子通路抑制物2(tissue factor pathway inhibitor 2,TFPI2)基因甲基化检测在结直肠癌前瞻性筛查中的临床性能。
方法
2
以常规体检的受试者作为研究对象,收集受试者的粪便样本并用SDC2和TFPI2基因甲基化试剂盒进行检测。试剂盒检测结果为阳性的受试者推荐其进行肠镜检查。
结果
2
1 215例受试者接受了粪便SDC2和TFPI2基因甲基化检测,包括708例男性和507例女性,平均年龄为(44.7±13.9)岁。其中有28例受试者的检测结果为阳性,阳性率为2.30%。阳性受试者接受肠镜检查的比例为96.43%(27/28),异常肠镜检查结果的比例为59.26%(16/27)。以肠镜和(或)病理检查作为诊断标准,该试剂盒对结直肠癌、进展期腺瘤和非进展期腺瘤的阳性预测值分别为7.41%、22.22%和7.41%。
结论
2
粪便SDC2和TFPI2基因甲基化检测在前瞻性的结直肠癌筛查中展示出良好的性能,为结直肠癌的筛查和辅助诊断提供了一种无创的方法。
Objective
2
To investigate the clinical performance of fecal syndecan 2(SDC2)/tissue factor pathway inhibitor 2(TFPI2) gene methylation assay in prospective colorectal cancer screening.
Methods
2
The individuals who underwent routine physical examination were enrolled as subjects,and their fecal samples were collected and tested with fecal SDC2/TFPI2 gene methylation assay. In addition,enteroscopy was recommended for the subjects with positive results.
Results
2
A total of 1215 subjects received fecal SDC2/TFPI2 gene methylation assay,among whom there were 708 male subjects and 507 female subjects,with a mean age of (44.7±13.9) years. Among all subjects,28 had positive test results,resulting in a positive rate of 2.30%,and among these 28 subjects,27(96.43%) underwent enteroscopy,among whom 16(59.26%) had abnormal findings. With enteroscopy and/or pathological examination as diagnostic criteria,fecal SDC2/TFPI2 gene methylation assay had a positive predictive value of 7.41% for colorectal cancer,22.22% for progressive precancerous lesion,and 7.41% for non-progressive precancerous lesion.
Conclusion
2
Fecal SDC2/TFPI2 gene methylation assay shows good clinical performance in prospective colorectal cancer screening and thus provides a noninvasive method for the screening and auxiliary diagnosis of colorectal cancer.
Sung H , Ferlay J , Siegel RL , et al . Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J ] . CA Cancer J Clin , 2021 , 71 ( 3 ): 209 - 249 .
黄 庆 , 索彩霞 , 何 凤 , 等 . 结直肠癌的早期诊断策略和治疗进展 [J ] . 广州医药 , 2024 , 55 ( 1 ): 1 - 8,53 .
Huang Q , Suo CX , He F , et al . Early diagnostic strategies and therapeutic advances in colorectal cancer [J ] . Guangzhou Med J , 2024 , 55 ( 1 ): 1 - 8,53 .
Shaukat A , Levin TR . Current and future colorectal cancer screening strategies [J ] . Nat Rev Gastroenterol Hepatol , 2022 , 19 ( 8 ): 521 - 531 .
Dekker E , Tanis P J , Vleugels JLA , et al . Colorectal cancer [J ] . Lancet , 2019 , 394 ( 10207 ): 1467 - 1480 .
Cronin KA , Scott S , Firth AU , et al . Annual report to the nation on the status of cancer,part 1:National cancer statistics [J ] . Cancer , 2022 , 128 ( 24 ): 4251 - 4284 .
Chen HD , Li N , Ren JS , et al . Participation and yield of a population-based colorectal cancer screening programme in China [J ] . Gut , 2019 , 68 ( 8 ): 1450 - 1457 .
Imperiale TF , Ransohoff DF , Itzkowitz SH , et al . Multitarget stool DNA testing for colorectal-cancer screening [J ] . N Engl J Med , 2014 , 370 ( 14 ): 1287 - 1297 .
Imperiale TF , Porter K , Zella J , et al . Next-generation multitarget stool DNA test for colorectal cancer screening [J ] . N Engl J Med , 2024 , 390 ( 11 ): 984 - 993 .
Zhang WS , Yang CG , Wang SY , et al . SDC2 and TFPI2 methylation in stool samples as an integrated biomarker for early detection of colorectal cancer [J ] . Cancer Manag Res , 2021 , 13 : 3601 - 3617 .
Wang ZX , Shang J , Zhang GN , et al . Evaluating the clinical performance of a dual-target stool DNA test for colorectal cancer detection [J ] . J Mol Diagn , 2022 , 24 ( 2 ): 131 - 143 .
Inadomi JM , Vijan S , Janz NK , et al . Adherence to colorectal cancer screening:a randomized clinical trial of competing strategies [J ] . Arch Intern Med , 2012 , 172 ( 7 ): 575 - 582 .
Nikanjam M , Kato S , Kurzrock R . Liquid biopsy:current technology and clinical applications [J ] . J Hematol Oncol , 2022 , 15 ( 1 ): 131 .
Luo HY , Wei W , Ye ZY , et al . Liquid biopsy of methylation biomarkers in cell-free DNA [J ] . Trends Mol Med , 2021 , 27 ( 5 ): 482 - 500 .
Porcaro F , Voccola S , Cardinale G , et al . DNA methylation biomarkers in stool samples:enhancing colorectal cancer screening strategies [J ] . Oncol Rev , 2024 , 18 : 1408529 .
Zhao FQ , Bai P , Xu JF , et al . Efficacy of cell-free DNA methylation-based blood test for colorectal cancer screening in high-risk population:a prospective cohort study [J ] . Mol Cancer , 2023 , 22 ( 1 ): 157 .
Oh TJ , Oh HI , Seo YY , et al . Feasibility of quantifying SDC2 methylation in stool DNA for early detection of colorectal cancer [J ] . Clin Epigenetics , 2017 , 9 : 126 .
Glöckner SC , Dhir M , Yi JM , et al . Methylation of TFPI2 in stool DNA:a potential novel biomarker for the detection of colorectal cancer [J ] . Cancer Res , 2009 , 69 ( 11 ): 4691 - 4699 .
储梦真 , 唐宜桂 , 张 敏 , 等 . SDC2和TFPI2基因甲基化联合检测在结直肠癌早期筛查中的应用价值 [J ] . 安徽医科大学学报 , 2023 , 9 ( 4 ): 682 - 686 .
Chu MZ , Tang YG , Zhang M , et al . The value of combined SDC2 and TFPI2 gene methylation testing in the early screening of colorecta l cancer [J ] . Acta Univ Med Anhui , 2023 , 9 ( 4 ): 682 - 686 .
Liu S , Wang Y , Zhuo D , et al . 564P A large-scale real-world study for colorectal cancer screening [J ] . Ann Oncol , 2023 , 34 : S418 .
Li QZ , Jiang WC , Zhang YY , et al . Methylation of Septin9,SRSF1,and PAX8 in early screening of colorectal cancer in the population undergoing physical examinations [J ] . Clin Lab , 2023 , 69 ( 12 ): 1189 - 1203 .
Siegel R , Miller KD , Wagle NS , et al . Cancer statistics,2023 [J ] . CA Cancer J Clin , 2023 , 73 : 17 - 48 .
(责任编辑:周一青)
0
浏览量
4
下载量
0
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备11010802024621